Literature DB >> 19366582

Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK.

Philip D Minor1, Othmar G Engelhardt, John M Wood, James S Robertson, Simone Blayer, Tony Colegate, Luc Fabry, Jacco G M Heldens, Yoichiro Kino, Otfried Kistner, Ronald Kompier, Keiichi Makizumi, Jeroen Medema, Shigetaka Mimori, David Ryan, Richard Schwartz, Jonathan S B Smith, Keishin Sugawara, Heidi Trusheim, Theodore F Tsai, Ryoko Krause.   

Abstract

A meeting was held at NIBSC, UK in July 2007 to discuss the implications of progress in the use of cell culture systems for the manufacture of vaccines against influenza. Issues discussed included the effect of using eggs and different cell types in strain selection, development of seed viruses to be used in production and the nature of the reagents to be used in determining vaccine potency. Future studies to progress the field were reviewed.

Mesh:

Substances:

Year:  2009        PMID: 19366582     DOI: 10.1016/j.vaccine.2009.02.064

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  22 in total

Review 1.  Glycomics and glycoproteomics of viruses: Mass spectrometry applications and insights toward structure-function relationships.

Authors:  John F Cipollo; Lisa M Parsons
Journal:  Mass Spectrom Rev       Date:  2020-04-29       Impact factor: 10.946

2.  Bringing influenza vaccines into the 21st century.

Authors:  Ethan C Settembre; Philip R Dormitzer; Rino Rappuoli
Journal:  Hum Vaccin Immunother       Date:  2013-12-30       Impact factor: 3.452

3.  Vaccine production, distribution, access, and uptake.

Authors:  Jon Smith; Marc Lipsitch; Jeffrey W Almond
Journal:  Lancet       Date:  2011-06-12       Impact factor: 79.321

4.  An MDCK cell culture-derived formalin-inactivated influenza virus whole-virion vaccine from an influenza virus library confers cross-protective immunity by intranasal administration in mice.

Authors:  Ahmad M Haredy; Nobuyuki Takenaka; Hiroshi Yamada; Yoshihiro Sakoda; Masatoshi Okamatsu; Naoki Yamamoto; Takeshi Omasa; Hisao Ohtake; Yasuko Mori; Hiroshi Kida; Koichi Yamanishi; Shigefumi Okamoto
Journal:  Clin Vaccine Immunol       Date:  2013-05-01

5.  Protease activation mutants elicit protective immunity against highly pathogenic avian influenza viruses of subtype H7 in chickens and mice.

Authors:  Ralf Wagner; Gülsah Gabriel; Matthias Schlesner; Nina Alex; Astrid Herwig; Ortrud Werner; Hans-Dieter Klenk
Journal:  Emerg Microbes Infect       Date:  2013-02-27       Impact factor: 7.163

6.  Production of inactivated influenza H5N1 vaccines from MDCK cells in serum-free medium.

Authors:  Alan Yung-Chih Hu; Yu-Fen Tseng; Tsai-Chuan Weng; Chien-Chun Liao; Johnson Wu; Ai-Hsiang Chou; Hsin-Ju Chao; Anna Gu; Janice Chen; Su-Chen Lin; Chia-Hsin Hsiao; Suh-Chin Wu; Pele Chong
Journal:  PLoS One       Date:  2011-01-24       Impact factor: 3.240

7.  Adaptation of high-growth influenza H5N1 vaccine virus in Vero cells: implications for pandemic preparedness.

Authors:  Yu-Fen Tseng; Alan Yung-Chih Hu; Mei-Liang Huang; Wei-Zhou Yeh; Tsai-Chuan Weng; Yu-Shuan Chen; Pele Chong; Min-Shi Lee
Journal:  PLoS One       Date:  2011-10-13       Impact factor: 3.240

8.  The neuraminidases of MDCK grown human influenza A(H3N2) viruses isolated since 1994 can demonstrate receptor binding.

Authors:  Peter G Mohr; Yi-Mo Deng; Jennifer L McKimm-Breschkin
Journal:  Virol J       Date:  2015-04-22       Impact factor: 4.099

9.  Host Adaptation and the Alteration of Viral Properties of the First Influenza A/H1N1pdm09 Virus Isolated in Japan.

Authors:  Akira Ainai; Hideki Hasegawa; Masatsugu Obuchi; Takato Odagiri; Makoto Ujike; Masayuki Shirakura; Eri Nobusawa; Masato Tashiro; Hideki Asanuma
Journal:  PLoS One       Date:  2015-06-16       Impact factor: 3.240

10.  Efficient generation of influenza virus with a mouse RNA polymerase I-driven all-in-one plasmid.

Authors:  Xiangmin Zhang; Roy Curtiss
Journal:  Virol J       Date:  2015-06-22       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.